The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property.

Moses Elisaf(University of Ioannina), Nikolaos Pavlidis(University Hospital of Ioannina), C. Nicolaides(University Hospital of Ioannina), C. Tzallas, K. C. Siamopoulos, Eleni Bairaktari(University of Ioannina), Orestes Tsolas, George Fountzilas(Hellenic Cooperative Oncology Group)
PubMed
December 18, 1996
Cited by 33

Related Papers

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
|Metabolism|2017|251
The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology
|International Journal of Molecular Sciences|2022|214
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
|Current Vascular Pharmacology|2011|197
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2010|166
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160